🗝️The right drug molecule will bind to a protein to treat a disease. But what about "undruggable targets"? #JClinic PIs @BarzilayRegina & @MarzyehGhassemi co-authored a new paper in @NatureBiotech w/ 15 co-authors on how AI could challenge drug design. https://t.co/IewlHEAeRj

@HarmonicDiscov, @rayrah_, and @CichonskaAnna present a method that enhances compound bioactivity modeling by integrating diverse data types, enabling cost-effective training data generation. https://t.co/tobrltzEKl

Excited to share our paper published in @NatureComms led by @rythei & @CichonskaAnna! By integrating diverse bioactivity datatypes, we built a best-in-class drug-target interaction model called Kanopy—achieving an experimentally confirmed prospective hit rate of 40% (at 1µM)!

We are thrilled to announce that we are in-licensing an asset developed by Professors Hong-Yu Li, PhD (previously of UAMS) and Neil Shah, MD PhD (UCSF) for FLT3 mutant AML! Learn more in our press release below! https://t.co/Ti6x1cySFy

Congratulations to the HD team for their newly published article! We are strong supporters of the peer review process and aim to have all of our public work in great journals.

Also at #ACSFall2023 check out our talk on leveraging 3D features derived from AlphaFold2 structures to improve protein-ligand affinity predictions!

Excited to share DockDB to the public! DockDB is a an all-inclusive Relational Database Management System (RDBMS) for molecular docking experiments. Find out more at our blog post here, we are also presenting more at #ACSFall2023

We are thrilled to share early work on leveraging AlphaFold2 to explore the conformational diversity of kinases! This work was led by led by @carmenmasri and Francesco Trozzi. A poster was presented last week at @workshopmlsb. Please take a look here: https://t.co/q01n0ZZTyC

Announcing our investment in a team that embraces the complexity of kinase therapeutics — @HarmonicDiscov. Once considered undruggable, kinases are critical nodes in oncology and inflammatory diseases + are involved in functions like cell growth/survival.

I’m thrilled to be a part of this journey!

It's hard to find a good mentor. We are extremely grateful for having the opportunity to participate in the JPALS program and to be part of the @JLABS ecosystem of companies!

Results of the IDG-DREAM Challenge comparing algorithms to predict kinase inhibitor activities @CichonskaAnna @allawayr @dr_e_a_m @Sagebio @DruggableGenome @csaalto @HIIT @FIMM_UH @Oslounivsykehus @OCBE_UniOslo @OusResearch @gururavikumar1 @WennerbergLab https://t.co/66apsu2m5t

Nightingale has entered into a service agreement with Mitsui & Co.’s fully owned subsidiary (Welltus Inc.) to sell health and well-being services in the Japanese market. Read more:

Based on scientific findings, @NgaleHealth will launch a screening tool for detecting those at high risk for getting severe symptoms if infected by #coronavirus. The risk estimate is based on molecular signatures in blood. https://t.co/ta8O9Xo03V #prevention #COVIDー19

What happens once the central banks’ trillions are spent? More trillions? This is not a long-term solution. We need to prevent shutdowns while still slowing down the virus outbreak. #covid19

The reason why we've cancelled bookings at Nightingale Nest for the next weeks. #CoronaOutbreak #FlattenTheCurve #prevention #StayHealthy Hopefully, the situation stabilises & we all go back to our regular schedules soon. 📊source: @nytimes

FDA approves new oral, once-a-day bempedoic acid for LDL-lowering. https://t.co/nL2D3uAaPo #cardiotwitter

JUST IN: Yrjö Närhinen joins Nightingale as an investor & strategic advisor. Närhinen, best known for his role as the former CEO of Terveystalo––the largest private healthcare service in Finland, will help accelerate our international growth. More 👉 https://t.co/7GvyNzbhv2

With @allawayr @FIMM_UH @Sagebio @dhdrewry @SchlessingerLab @justin_guinney @UCPH_BRIC @UNC @olexandr and many others.

Our preprint describing the results of the DREAM challenge on drug-kinase binding prediction is out! Co-organizing this challenge has been an amazing journey. Many thanks to everyone involved!